Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 7677 results found since Jan 2013.
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer
CONCLUSIONS: There was no evidence for or against debulking hysterectomy followed by CCRT versus CCRT alone for FIGO (2019) stage IB3/II cervical cancer.PMID:36111784 | DOI:10.1002/14651858.CD012246.pub2
Source: Cochrane Database of Systematic Reviews - September 16, 2022 Category: General Medicine Authors: Manas Chakrabarti Andy Nordin Juneida Khodabocus Source Type: research
Cervical Cancer and Human Papillomavirus Vaccine Knowledge, Utilisation, Prevention Educational Interventions and Policy Response in Nigeria: A Scoping Review
CONCLUSION: Knowledge and uptake of cervical cancer preventive services across diverse groups in Nigeria remain poor. These could be linked to socio-cultural factors, the lack of an organised cervical cancer screening programme and low financial resource pool for cervical cancer prevention. Therefore, it is necessary to increase government, donor prioritisation and political support in order to ensure increased investment and commitment to cervical cancer elimination in Nigeria.PMID:36168955 | DOI:10.1177/10732748221130180
Source: Cancer Control - September 28, 2022 Category: Cancer & Oncology Authors: Yetunde O John-Akinola Chizoma M Ndikom Mojisola M Oluwasanu Temitayo Adebisi Oluwaponmile Odukoya Source Type: research
Implications of the non-specific effect induced by Bacillus Calmette-Guerin (BCG) vaccine on vaccine recommendations
CONCLUSIONS: Despite evidence obtained from in vitro studies, and some epidemiological and clinical evidence, more robust evidence of in vivo efficacy is still needed to justify the use of BCG in clinical practice, in addition to what is recommended by the National Immunization Program for TB prevention and bladder cancer treatment.PMID:36309066 | DOI:10.1016/j.jped.2022.09.002
Source: Cancer Control - October 29, 2022 Category: Cancer & Oncology Authors: Ekaterini Goudouris Carolina Sanchez Aranda Dirceu Sol é Source Type: research
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
Nat Cancer. 2022 Dec 29. doi: 10.1038/s43018-022-00503-w. Online ahead of print.ABSTRACTPatients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE ) in hospitalized patients with severe...
Source: Cancer Control - December 29, 2022 Category: Cancer & Oncology Authors: Claudia M Denkinger Maike Janssen Ulrike Sch äkel Julia Gall Albrecht Leo Patrick Stelmach Stefan F Weber Johannes Krisam Lukas Baumann Jacek Stermann Uta Merle Markus A Weigand Christian Nusshag Lars Bullinger Jens-Florian Schrezenmeier Martin Bornh äu Source Type: research
Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis
CONCLUSION: Cytotoxic therapy for solid cancer may portend poor immune response following 2 doses of COVID-19 vaccines suggesting a need for booster doses in these patients. Immunotherapy and targeted therapy are likely to be associated with seropositive status, and thus can be considered as an alternative to cytotoxic agents in cases where both therapies are equally efficacious.PMID:36792435 | DOI:10.1016/j.vaccine.2023.01.072
Source: Vaccine - February 15, 2023 Category: Allergy & Immunology Authors: Durgesh Wankhede Sandeep Grover Paul Hofman Source Type: research
The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I-associated peptides
Cancer Immunol Res. 2023 Mar 24:CIR-22-0621. doi: 10.1158/2326-6066.CIR-22-0621. Online ahead of print.ABSTRACTTumor antigens can emerge through multiple mechanisms, including translation of non-coding genomic regions. This non-canonical category of antigens has recently gained attention; however, our understanding of how they recur within and between cancer types is still in its infancy. Therefore, we developed a proteogenomic pipeline based on deep learning de novo mass spectrometry to enable the discovery of non-canonical MHC-associated peptides (ncMAPs) from non-coding regions. Considering that the emergence of tumor a...
Source: Cell Research - March 24, 2023 Category: Cytology Authors: Georges Bedran Hans-Christof Gasser Kenneth Weke Tongjie Wang Dominika Bedran Alexander Laird Christophe Battail Fabio Massimo Zanzotto Catia Pesquita H åkan Axelson Ajitha Rajan David J Harrison Aleksander Palkowski Maciej Pawlik Maciej Parys J Robert O Source Type: research
Project ECHO for Cancer Care: a Scoping Review of Provider Outcome Evaluations
J Cancer Educ. 2023 Mar 31. doi: 10.1007/s13187-023-02292-x. Online ahead of print.ABSTRACTThe Project ECHO model of telementoring has been used for the past 10 years to expand access to specialized cancer care. This scoping review identifies evidence for the model's ability to improve provider outcomes, synthesizing findings from existing studies within Moore et al.'s (2009) framework for continuing medical education outcomes. We search two large research databases and a collection maintained by Project ECHO staff for articles that focus on cancer ECHO programs, involve primary data collection, and were published between ...
Source: Cancer Control - March 31, 2023 Category: Cancer & Oncology Authors: Sanjeev Arora Heidi Rishel Brakey Jessica L Jones Nancy Hood Jesus E Fuentes Lucca Cirolia Source Type: research
